今年以来,创新药赛道持续受到政策关注与市场瞩目。我国创新药市场的发展也给跨国药企带来更多机遇。加码中国创新,跨国药企如何布局?第一财经《首席评论》近期专访了百时美施贵宝副总裁、中国及亚洲区域市场总经理陈思渊,共同探讨相关话题。第一财经:百时美施贵宝在2020年提出了 “中国2030战略”,目前进展如何?陈思渊:百时美施贵宝“中国2030战略”的目标是把更多的创新药物在第一时间带给中国患者,在中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.